Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

Kirby Institute27 enrolled

Overview

CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.

Study Type

OBSERVATIONAL

Enrollment

Conditions

HIV-1-infection Cancer Primary Immune Deficiency Disorder Immunosuppression Disorders COVID-19

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Presenting (in person or via telemedicine) for evaluation because they: * Have clinical symptoms consistent with for COVID-19: * Fever (≥ 37.8 °C) on examination OR patient reported fever (≥ 37.8 °C) or feverishness (felt febrile but did not take temperature) OR any of, cough, sore throat, shortness of breath, rhinorrhoea, headache, chills, generalise myalgia, malaise, fatigue, confusion, diarrhea, nausea or vomiting * Have been contacted because they have been identified as a contact to a confirmed case * Have been contacted and told they tested positive for COVID-19 2. Have one of the following conditions affecting immune function: * Known or suspected primary immunodeficiency, defined as a predisposition to infection associated with an apparent or presumed deficit of immune function * On immunosuppressive therapy * Treatment with immune checkpoint inhibitors within 36 months of enrolment date * HIV infection * Diagnosis of cancer within 36 months of enrolment date, excluding superficial basal cell and squamous cell carcinomas * Solid organ transplantation 3. For optional biobanking only, ability to provide informed consent Exclusion Criteria: * Nil